Get started

Financials · ACH

Accendra Health Inc. (ACH) financials

For the twelve months ended Sep 30, 2026, Accendra Health Inc. reported $2.55B of revenue and -$171.56M of net income.

Revenue, TTM
$2.55B
Revenue growth, YoY
-7.1%
Net income, TTM
-$171.56M
Net margin
-6.7%
Free cash flow, TTM
-$199.12M
EPS, diluted, TTM
-$2.24
Cash
$26.61M
Total debt
$1.75B
P/S
0.01
Market cap
$14.2M
Annual revenue$2.76B
FY2016FY2025
Annual net income-$1.10B
FY2016FY2025
Annual free cash flow-$292.75M
FY2016FY2025

ACH revenue and earnings growth

ACH revenueQ3 2026$601.77M

Quarter YoY
-13.7%
QoQ
-1.9%
FY YoY
+3.1%
5Y CAGR
-20.1%
10Y CAGR
-11.9%

ACH revenue was $601.77M in fiscal Q3 2026 (ended Sep 30, 2026), down 13.7% from a year earlier and down 1.9% from the prior quarter. For the full fiscal 2025 it was $2.76B, up 3.1% from fiscal 2024. Compound annual growth was -20.1% over 5 years and -11.9% over 10 years. It rose in 5 of the last 10 fiscal years.

ACH net incomeQ3 2026-$19.70M

ACH net income was -$19.70M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$150.28M a year earlier. For the full fiscal 2025 it was -$1.10B, compared with -$362.69M in fiscal 2024.

ACH EPSQ3 2026-$0.25

ACH diluted EPS was -$0.25 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$1.94 a year earlier. For the full fiscal 2025 it was -$14.31, compared with -$4.73 in fiscal 2024.

ACH free cash flowQ3 2026-$56.58M

ACH free cash flow was -$56.58M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$214.65M a year earlier. For the full fiscal 2025 it was -$292.75M, compared with -$8.79M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$2.76B$2.68B$2.55B$9.96B$9.79B$8.48B$9.21B$9.42B$9.32B$9.72B
Cost of revenue$1.47B$1.40B$1.34B$8.13B$8.27B$7.20B$8.08B$8.35B$8.15B$8.54B
Gross profit$1.29B$2.22B$2.13B$1.83B$1.51B$1.28B$1.13B$1.07B$1.17B$1.19B
Research and development-$13.00M$13.00M$12.00M$12.10M-----
Selling, general and admin$1.07B$1.08B$1.00B$1.55B$1.08B$1.04B$1.02B$952.87M$1.02B$970.42M
Operating income$27.46M-$217.73M$133.23M$142.91M$368.47M$204.12M$73.15M-$352.35M$89.25M$199.60M
Interest expense$107.18M$107.57M$116.77M$128.89M$48.09M$83.40M$98.11M$70.98M$31.77M$27.06M
Pre-tax income-$101.95M-$329.88M$15.27M$10.89M$276.75M$109.91M-$28.72M-$427.09M$57.48M$172.54M
Income tax$729.0K$20.85M$6.36M-$11.50M$55.16M$21.83M-$6.13M-$32.43M-$15.31M$63.76M
Net income-$1.10B-$362.69M-$41.30M$22.39M$221.59M$29.87M-$62.37M-$437.01M$72.79M$108.79M
EPS, basic-$14.31-$4.73-$0.54$0.30$3.05$0.47-$1.03-$7.28$1.20$1.76
EPS, diluted-$14.31-$4.73-$0.53$0.29$2.94$0.47-$1.03-$7.28$1.20$1.76
Diluted shares76.9M76.7M77.4M76.2M75.5M63.5M60.6M60.0M60.0M61.1M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$281.99M$27.57M$272.92M$86.19M$72.03M$134.51M$84.69M$103.37M$104.52M$185.49M
Inventory$74.44M$67.58M$1.11B$1.33B$1.50B$1.23B$1.15B$1.27B$990.19M$916.31M
Current assets$547.87M$2.02B$2.10B$2.30B$2.32B$2.14B$2.41B$2.54B$2.18B$1.96B
Goodwill$1.23B$1.23B$1.64B$1.64B$390.19M$394.09M$393.18M$414.12M$686.96M$414.94M
Total assets$2.45B$4.66B$5.09B$5.39B$3.54B$3.34B$3.64B$3.77B$3.38B$2.72B
Current liabilities$947.08M$1.85B$1.89B$1.57B$1.34B$1.35B$1.42B$1.47B$1.31B$1.03B
Short-term debt$250.00M$42.87M$206.90M$17.91M-$39.95M$51.24M$28.69M$16.62M$4.80M
Long-term debt$1.80B$1.80B$1.89B$2.48B$947.54M$986.02M$1.51B$1.65B$900.74M$564.58M
Total debt$2.05B$1.84B$2.10B$2.50B$947.54M$1.03B$1.56B$1.68B$917.36M$569.39M
Total liabilities$2.91B$4.07B$4.17B$4.44B$2.60B$2.62B$3.18B$3.26B$2.36B$1.76B
Shareholders' equity-$460.98M$586.36M$945.30M$966.74M$938.50M$712.05M$462.15M$518.42M$1.02B$960.04M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$101.79M$161.50M$740.71M$325.01M$124.18M$339.22M$166.09M$115.59M$56.77M$187.69M
Capital expenditures$190.96M$170.29M$172.38M$158.09M$40.98M$50.42M$42.42M$44.87M$34.61M$20.30M
Free cash flow-$292.75M-$8.79M$568.34M$166.92M$83.19M$288.80M$123.67M$70.72M$22.16M$167.39M
Investing cash flow$144.42M-$116.53M-$137.25M-$1.80B-$53.63M$80.07M-$51.90M-$815.83M-$416.64M-$24.75M
Financing cash flow$188.08M-$267.60M-$417.33M$1.50B-$129.48M-$379.39M-$130.20M$701.07M$272.81M-$142.70M
Dividends paid--$0$0$731.0K$648.0K$5.23M$48.20M$63.15M$63.38M
Share repurchases$10.18M------$0$5.00M$71.03M
Stock-based compensation$12.87M$16.64M$14.39M$20.99M$25.02M$20.01M$15.80M$16.38M$11.91M$12.04M
Depreciation and amortization$214.52M$181.28M$210.37M$228.67M$90.62M$93.34M$116.68M$101.93M$59.44M$55.39M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY3.1%5.0%-74.4%1.7%15.4%-7.9%-2.2%1.1%-4.2%-0.5%
Net income growth, YoY----89.9%641.8%----33.1%5.2%
EPS growth, YoY----90.1%525.5%----31.8%6.7%
Gross margin46.7%82.8%83.3%18.3%15.5%15.1%12.3%11.4%12.6%12.2%
Operating margin1.0%-8.1%5.2%1.4%3.8%2.4%0.8%-3.7%1.0%2.1%
Net margin-39.8%-13.5%-1.6%0.2%2.3%0.4%-0.7%-4.6%0.8%1.1%
Free cash flow margin-10.6%-0.3%22.3%1.7%0.9%3.4%1.3%0.8%0.2%1.7%
Return on equity--61.9%-4.4%2.3%23.6%4.2%-13.5%-84.3%7.2%11.3%
Return on assets-44.9%-7.8%-0.8%0.4%6.3%0.9%-1.7%-11.6%2.2%4.0%
Current ratio0.581.091.111.471.731.591.701.721.671.90
Debt to equity-3.142.222.591.011.443.373.230.900.59

Source: XBRL data Accendra Health Inc. files with the SEC, latest filing dated Nov 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

ACH peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
ACH$2.55B-7.1%-$171.56M-6.7%$14.2M
UNH$449.66B+3.3%$15.88B3.5%$356.28B
ELV$201.83B+3.6%$5.13B2.5%$90.37B
CI$286.32B+6.8%$5.99B2.1%$77.89B
HUM$154.19B+22.0%$1.25B0.8%$50.82B
NTRA$2.91B+37.4%-$164.71M-5.7%$46.46B
CNC$203.90B+9.7%$1.46B0.7%$33.93B
ILMN$4.54B+5.8%$895.00M19.7%$33.38B
LH$14.59B+6.0%$1.00B6.9%$30.19B

ACH FAQ

9 questions
  • What is ACH revenue?
    Accendra Health Inc. (ACH) reported $2.55B of revenue for the twelve months ended Sep 30, 2026. That is down 7.1% from the year before. Revenue for fiscal 2025 was $2.76B.
  • Is ACH profitable?
    No. Accendra Health Inc. reported a net loss of $171.56M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does ACH have?
    Accendra Health Inc. reported $26.61M in cash and cash equivalents and $1.75B of debt on its most recent balance sheet in SEC filings.
  • How fast is ACH revenue growing?
    Accendra Health Inc.'s revenue changed +3.1% in fiscal 2025, to $2.76B. Its compound annual growth rate was -20.1% over 5 years and -11.9% over 10 years.
  • What is ACH gross margin?
    Accendra Health Inc.'s gross profit was $1.13B on $2.55B of revenue for the twelve months ended Sep 30, 2026, a gross margin of 44.1%.
  • What is ACH free cash flow?
    Accendra Health Inc. generated -$199.12M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$25.31M less capital expenditures.
  • What is ACH earnings per share?
    Diluted earnings per share were -$2.24 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did ACH last report financial results?
    The latest statements here come from Accendra Health Inc.'s 10-Q filed on Nov 6, 2026, covering the period ended Sep 30, 2026.
  • Where does this ACH financial data come from?
    Quantisnow builds these statements from the structured XBRL data Accendra Health Inc. files with the SEC. It is provided for information only and is not investment advice.